DHG: Explanation for business results in 2013 before & after review

DHG Pharmaceutical Joint Stock Company has explained for business results in 2013 before & after review as follows:

1.     Financial Statement of parent company:

	Before review	After review	Different	Rate (%)
Revenue from selling and service supply	3,254,187,337,448	3,254,187,337,448
Cost of goods sold	1,878,985,343,814	1,878,985,343,814
Financial income	122,441,403,517	122,441,403,517
Financial expense	10,131,629,848	14,645,511,298	-4,513,881,450	-30.82%
Selling expense	663,242,886,963	659,189,679,313	4,053,207,650	0.61%
General and administration expense	208,369,805,247	206,978,616,605	1,391,188,642	0.67%
Other income	153,910,778,909	147,806,838,794	6,103,940,115	4.13%
Profit before tax	769,809,854,002	764,636,428,729	5,173,425,273	0.68%

 

Reason:

-  Financial expense decreased because the firm delayed long term investment provision in Financial Statement of Binh Duong Pharmaceutical and medical supplies Joint Stock Company,  Nghe An Pharmaceutical and medical supplies Joint Stock Company, TV. Pharm Pharmaceutical Joint Stock Company.

-  Selling expense increased because the firm adjusted promotion expenses.

-  Other income increased because the firm recognized commission from MSD custom.

 

2.     Consolidated Financial Statement:

	Before review	After review	Different	Rate (%)
Revenue from selling and service supply	3,527,357,300,211	3,527,357,300,213	-2
Cost of goods sold	1,886,883,559,265	1,886,952,399,113	-68,839,848
Financial income	47,969,788,627	47,969,788,627
Financial expense	16,455,522,775	20,969,404,225	-4,513,881,450	-21.53%
Selling expense	770,103,406,614	766,061,926,237	4,041,480,377	0.53%
General and administration expense	270,757,905,732	264,468,164,539	6,289,741,193	2.38%
Other income	150,373,721,885	144,803,316,712	5,570,405,173	3.85%
Profit before tax	781,500,416,337	781,678,511,438	-178,095,101	-0.02%

 

Reason:

·         Cost of goods sold decreased because the firm delayed provision for devaluation inventories.

·         Financial Statement of Binh Duong Pharmaceutical and medical supplies Joint Stock Company, Nghe An Pharmaceutical and medical supplies Joint Stock Company, TV. Pharm Pharmaceutical Joint Stock Company.

·         Selling expense increased because the firm adjusted promotion expenses.

·         General and administration expense increased because the firm increased labor expense in 2013 and the firm made reserve for bad debts.

·         Other income increased because the firm recognized commission from MSD custom.

 

HOSE

>   ACC: Notice of the 2014 AGM (24/03/2014)

>   CTD: Notice of the 2014 AGM (24/03/2014)

>   LBM: Resolution on organizing the AGM 2014 (24/03/2014)

>   PXM: Resolution on organizing the AGM 2014 and business plan for 2014 (24/03/2014)

>   TMT: Notice of the 2014 AGM (24/03/2014)

>   VTB: Notice of the 2014 AGM (24/03/2014)

>   DZM: Explanation for the difference in operating result of FS QIV.2013 (24/03/2014)

>   DZM: Explanation for Financial statement 2013 (24/03/2014)

>   ECI: Explanation for the difference in profit after tax of FS 2013 (24/03/2014)

>   FIT: Explanation for the difference in profit after tax in the financial statement of Q.IV/2013 compared to the audited financial statement of 2013 (24/03/2014)